Biocon Limited has informed the Exchange regarding Outcome of Board Meeting held on March 27, 2026 - Change in KMP and SMP
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Biocon's board has approved a major leadership reshuffle effective April 1, 2026, as part of its plan to integrate Biocon Biologics into a single global biopharmaceutical company. CEO & Managing Director Siddharth Mittal and Interim CFO Mukesh Kamath have resigned from March 31, 2026 to move into other roles within the Biocon Group. Shreehas Pradeep Tambe, currently CEO of Biocon Biologics, will take over as the new CEO & MD for a 5-year term, subject to shareholder approval. Kedar Narayan Upadhye, CFO of Biocon Biologics, will become the new CFO. Additionally, 7 Senior Management Personnel have stepped down, and new CHRO, CTO, and Head of Governance, Risk & Compliance have been appointed, all internal transfers from Biocon Biologics.
This is a planned, strategic leadership transition tied to the Biocon-Biocon Biologics integration announced in December 2025, rather than a sudden exit. Both outgoing and incoming leaders remain within the Biocon Group, which should limit disruption. The new CEO has a strong track record, having scaled Biocon Biologics into a top-5 global biosimilars player, which may be viewed positively by investors.